FPT Launches AI-First Platform FleziPT, Accelerating Global Enterprise Transformation
13.8.2025 10:04:00 CEST | Business Wire | Press Release
Global IT firm FPT officially announced the launch of its new artificial intelligence (AI) platform, FleziPT. Designed to deliver end-to-end, customized AI-powered transformation solutions, FleziPT empowers organizations to achieve exceptional speed, precision, and quality in their transformation journeys. This launch strengthens FPT’s position as an AI-first company with full-stack AI capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812864322/en/
FPT Launches AI-First Platform FleziPT, Accelerating Global Enterprise Transformation
FleziPT is backed by the company’s AI-driven software development life cycle (SDLC), delivering intelligent solutions across key domains. It leverages an AI-augmented workforce, including 12,000 skilled software engineers proficient in AI and a million digital workers in the making globally.
The AI Platform allows enterprises to embed AI agents throughout every phase of software development, allowing tasks that previously took months in waterfall models or 4–6 weeks in agile sprints to be completed within days. This shift results in:
- Up to 60% faster development
- Over 50% reduction in rework
- 30% boost in productivity
These gains support faster iteration, concurrent workflows, and rapid delivery of results, driving precision and innovation at scale. FleziPT’s AI-driven SDLC also fuels FPT’s continuous reinvention, enabling real-time adaptation to evolving market demands through actionable AI insights.
Built on almost three decades of digital transformation expertise, FleziPT features a suite of proprietary AI toolsets, including solutions such as AgentVista, CodeVista, and TestVista. It also offers tailored solutions for vertical industries such as manufacturing, healthcare, finance, automotive, and energy, including AIDP and IvyChat, winners of the Globee® Technology Awards and International Business Awards® in 2024 and 2025.
To support the next-level AI transformation for global businesses across industries, FleziPT is also underpinned by AI-specific workforce accelerators. This includes AI education across all levels for FPT employees and at FPT University, which currently graduates 2,000 AI and Data Engineering students annually. FPT also fosters a co-creation relationship with its clients through AI labs and hackathons to address their specific challenges. These efforts are strengthened by FPT’s strategic partnerships with global leading AI players, including Microsoft, SAP, Landing AI, Mila - Quebec AI Institute, and notably NVIDIA with the joint initiative of FPT AI Factory. The company aims to train an additional 1,500+ AI experts by the end of 2025 and 50,000 specialists by 2030.
“We are not stopping at providing AI services. FPT is a full-fledged AI Global System Integrator, delivering scalable and trusted enterprise-grade AI solutions. We remain steadfast in our commitment to empowering clients worldwide with end-to-end AI enablement across industries, while upholding ethical and responsible AI practices,” said Pham Minh Tuan, FPT Software Chief Executive Officer and Executive Vice President, FPT Corporation.
The platform was launched during FPT’s 2025 global client event, themed “Danang – 20 Years of Innovation”, which marks the company’s two decades of growth in the city now central to its tech and education ecosystem. The event welcomed over 400 industry leaders and experts from around the world, featured an AI-focused tech exhibition and conference, spotlighting how AI is reshaping industries and reinforcing Vietnam’s position as a global innovation hub.
About FPT
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam and operates in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. Committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises, the Corporation focuses on three critical transformations: Digital Transformation, Intelligence Transformation, and Green Transformation. In 2024, FPT reported a total revenue of USD 2.47 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT's global IT services, please visit https://fptsoftware.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250812864322/en/
Contacts
Media Contact
Mai Duong (Ms.)
FPT Corporation
FPT Software PR Manager
MCP.PR@fpt.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom